Skip to main content
Advertisement
Advertisement

TSHA

TSHA logo

Taysha Gene Therapies, Inc. Common Stock

4.67
USD
Sponsored
-0.12
-2.51%
Sep 25, 15:59 UTC -4
Closed
exchange

After-Market

4.79

+0.13
+2.68%

TSHA Earnings Reports

Positive Surprise Ratio

TSHA beat 11 of 24 last estimates.

46%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$630.54K
/
-$0.13
Implied change from Q2 26 (Revenue/ EPS)
--
/
-7.14%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+44.44%

Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue

On Aug 11, 2026, TSHA reported earnings of -0.14 USD per share (EPS) for Q2 26, missing the estimate of -0.11 USD, resulting in a -17.75% surprise. Revenue reached --, compared to an expected 693.60 thousand, with a -100.00% difference. The market reacted with a -4.12% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 630.54 thousand USD, implying an decrease of -7.14% EPS, and -- of --% in Revenue from the last quarter.
FAQ
For Q2 2026, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.14, missing estimates by -17.75%, and revenue of $0.00, -100% below expectations.
The stock price moved down -4.12%, changed from $6.68 before the earnings release to $6.41 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 11 analysts, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $630.54K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement